Literature DB >> 34363257

Herpes zoster after inactivated SARS-CoV-2 vaccine in two healthy young adults.

A K Özdemir1, S Kayhan1, S K Çakmak1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34363257      PMCID: PMC8447007          DOI: 10.1111/jdv.17577

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   9.228


× No keyword cloud information.

Conflict of interest

Dr. Ahmet Kağan Özdemir does not report any conflict of interest. Dr. Sera Kayhan does not report any conflict of interest. Dr. Seray Külcü Çakmak does not report any conflict of interest. Dear editor, Coronavirus disease 2019 (COVID‐19) can cause various cutaneous manifestations that were identified since the outbreak. With the era of vaccination, cutaneous side effects of vaccines will likely be frequently encountered. Mild reactions like localized redness and swelling have been detected in vaccines reaching phase 3 trials; besides, rarer adverse effects such as injection site urticaria, maculopapular rash, reaction to dermal fillers due to COVID‐19 vaccines have been reported. COVID‐19 vaccine‐associated herpes zoster (HZ) has been described for the two most used vaccine types recently: Bostan and Yalici‐Armagan reported a 78‐year‐old man with thoracic HZ after administration of an inactivated vaccine, and Tessas and Kluger reported a 44‐year‐old man with cervical HZ after administration of a mRNA COVID‐19 vaccine. , In this case report, we present two immunocompetent young adults developing herpes zoster after inactivated severe acute respiratory syndrome coronavirus (SARS‐CoV‐2) vaccination. First case was a 23‐year‐old otherwise healthy woman who attended to our dermatology outpatient clinic with itchy and painful rash on her lower back. Her symptoms first appeared a day after she was vaccinated with inactivated SARS‐CoV‐2 vaccine. On examination, grouped vesicles on an erythematous base were noted. Lesions were confined in a single unilateral dermatome. She reported pain and itch which had started on the same day with rash. She was diagnosed with HZ and commenced on brivudine 125 mg tablet once daily for 7 days. Second case was a 21‐year‐old otherwise healthy man who presented with painful blisters at his abdomen (Figure 1). He was vaccinated with inactivated SARS‐CoV‐2 vaccine two days before his symptoms first appeared. On examination, painful eruption of grouped vesicles on an erythematous base in a single unilateral dermatome was observed. He was diagnosed with HZ, and valacyclovir 1 gr three times daily for seven days and analgesics were prescribed. Both patients stated that they had never experienced COVID‐19‐related symptoms since the beginning of pandemic, and they were well at the time of admission. After 14 days, both patients’ lesions disappeared completely; moreover, they did not experience neither COVID‐19‐related symptoms nor postherpetic neuralgia during that period.
Figure 1

Painful vesicles on an erythematous base in a dermatomal configuration on abdomen.

Painful vesicles on an erythematous base in a dermatomal configuration on abdomen. HZ is caused by reactivation of latent varicella zoster virus (VZV) in the sensory dorsal root ganglion. Age, stress, immunocompromised status and immunosuppressive drugs are risk factors for virus reactivation, mostly because these conditions lead to a reduction in VZV‐specific T cells. COVID‐19‐associated HZ has been reported previously, and the median time from hospitalization to HZ beginning was found as 5,5 days in series mainly involving older adults. The mechanism of SARS‐CoV‐2 induced HZ is yet to be discovered, but virus’s ability to deplete CD8+ T cells may reduce VZV‐specific T cells throughout infection. This case report describes highly possible inactivated SARS‐CoV‐2 vaccine‐related HZ in two healthy young adults. As HZ is rare in young and otherwise healthy adults, vaccine itself could be the trigger, but it is impossible to rule out reactivation of VZV by chance. Vaccines may cause immunomodulation and lead to herpes virus reactivation. Recently a case report of disseminated HZ after recombinant zoster vaccine was published, in which authors hypothesized that the immunostimulatory adjuvant in the vaccine could act as a physiologic stressor on the patient’s immune system, as a consequence patient’s cell‐mediated immunity towards VZV fell below the threshold of containment and permitted zoster reactivation. Short delay after vaccination, young age and previous reports , are arguments that support our cases’ link between HZ and vaccination. COVID‐19 vaccine‐associated HZ was not reported in published vaccine studies, , and case reports may help to define this possible side effect.

Funding source

None.
  10 in total

1.  Reactivation of herpesvirus infections after vaccinations?

Authors:  R Walter; K Hartmann; F Fleisch; W H Reinhart; M Kuhn
Journal:  Lancet       Date:  1999-03-06       Impact factor: 79.321

2.  Herpes zoster after recombinant zoster vaccine: A first case report.

Authors:  Laurie A Housel; Bruce M McClenathan
Journal:  J Allergy Clin Immunol Pract       Date:  2019-08-02

3.  Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence?

Authors:  Ecem Bostan; Basak Yalici-Armagan
Journal:  J Cosmet Dermatol       Date:  2021-03-08       Impact factor: 2.696

Review 4.  Epidemiology, treatment and prevention of herpes zoster: A comprehensive review.

Authors:  Elsam Koshy; Lu Mengting; Hanasha Kumar; Wu Jianbo
Journal:  Indian J Dermatol Venereol Leprol       Date:  2018 May-Jun       Impact factor: 2.545

5.  Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine.

Authors:  I Tessas; N Kluger
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-06-11       Impact factor: 9.228

6.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

Review 7.  The art of prevention: COVID-19 vaccine preparedness for the dermatologist.

Authors:  Shauna M Rice; Sarah D Ferree; Natasha Atanaskova Mesinkovska; Arianne Shadi Kourosh
Journal:  Int J Womens Dermatol       Date:  2021-01-12

Review 8.  Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives.

Authors:  Giovanni Genovese; Chiara Moltrasio; Emilio Berti; Angelo Valerio Marzano
Journal:  Dermatology       Date:  2020-11-24       Impact factor: 5.366

9.  Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

Authors:  Yanjun Zhang; Gang Zeng; Hongxing Pan; Changgui Li; Yaling Hu; Kai Chu; Weixiao Han; Zhen Chen; Rong Tang; Weidong Yin; Xin Chen; Yuansheng Hu; Xiaoyong Liu; Congbing Jiang; Jingxin Li; Minnan Yang; Yan Song; Xiangxi Wang; Qiang Gao; Fengcai Zhu
Journal:  Lancet Infect Dis       Date:  2020-11-17       Impact factor: 25.071

10.  Herpes zoster in COVID-19-positive patients.

Authors:  Federico Tartari; Alberto Spadotto; Corrado Zengarini; Rossana Zanoni; Alba Guglielmo; Alexander Adorno; Cinzia Valzania; Alessandro Pileri
Journal:  Int J Dermatol       Date:  2020-06-12       Impact factor: 2.736

  10 in total
  5 in total

Review 1.  A narrative review and clinical anatomy of herpes zoster infection following COVID-19 vaccination.

Authors:  Joe Iwanaga; Hiroshi Fukuoka; Nobuko Fukuoka; Hirokazu Yutori; Soichiro Ibaragi; R Shane Tubbs
Journal:  Clin Anat       Date:  2021-10-01       Impact factor: 2.414

2.  Potential risk factors for Varicella-zoster virus reactivation after COVID-19 vaccination.

Authors:  Marco May Lee; Stefano Macchi; Edoardo Mora; Claudio Feliciani
Journal:  J Cosmet Dermatol       Date:  2022-02-25       Impact factor: 2.189

Review 3.  SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.

Authors:  Gianluca Avallone; Pietro Quaglino; Francesco Cavallo; Gabriele Roccuzzo; Simone Ribero; Iris Zalaudek; Claudio Conforti
Journal:  Int J Dermatol       Date:  2022-02-09       Impact factor: 3.204

4.  Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus.

Authors:  M Hertel; M Heiland; S Nahles; M von Laffert; C Mura; P E Bourne; R Preissner; S Preissner
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-05-13       Impact factor: 9.228

5.  Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights.

Authors:  Raquel Martinez-Reviejo; Sofia Tejada; Ganiyat A R Adebanjo; Camilla Chello; Miriam C Machado; Francesca R Parisella; Magda Campins; Antonella Tammaro; Jordi Rello
Journal:  Eur J Intern Med       Date:  2022-08-01       Impact factor: 7.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.